Predictors of Cognitive Impairment among Filipino Patients with Type 2 Diabetes Mellitus in a Tertiary Government Hospital

Russell Anne Marie L. Carandang, MD, Marissa T. Ong, MD and Roy Alvin J. Malenab, MD

Department of Neurosciences, East Avenue Medical Center, East Avenue, Diliman, Quezon City

ABSTRACT

Background. Type 2 Diabetes Mellitus (T2DM) patients are predisposed to cognitive decline and dementia. The cooccurrence of the two diseases translate to a higher medical cost. Identification of factors contributing to cognitive impairment is warranted.

Objective. To determine the predictors of cognitive impairment among Filipino patients with Type 2 Diabetes Mellitus.

Methods. This is a cross-sectional analytical study involving Filipino patients diagnosed with T2DM in the outpatient clinic. A total of 171 patients were included and were screened using AD8-P tool.

Results. A total of 171 adult patients were included and screened for cognitive impairment.19.3% were cognitively impaired, with mean age of 59.6 years old (vs. 55.5 years old, p < 0.029), and two-thirds were female. The mean duration of the patient's diabetes was 11.2 years. After adjusting for confounders and multi-collinearity, the duration of diabetes was significantly associated with cognitive impairment with odds of developing cognitive impairment increasing as the duration reach 10 years above. Those with T2DM for at least ten years were 2.5 times more likely to develop cognitive impairment, holding the age constant. (OR = 2.5, 95% Cl – 1.0 to 5.8, p < 0.043).

Conclusion. 19.3% of Filipino patients with Type 2 Diabetes Mellitus in a tertiary government hospital are cognitively impaired and this can occur even in less than 65 years old. The ten years or longer duration of T2DM increases the risk of developing cognitive impairment by 2.5%.

Keywords: type 2 diabetes mellitus, cognitive impairment, cognitive dysfunction, dementia, aging, Alzheimer's Disease



Finalist – Philippine Neurological Association Research Contest, November 3, 2022 (via Zoom conference).

elSSN 2094-9278 (Online) Published: August 15, 2024 https://doi.org/10.47895/amp.vi0.7648

Corresponding author: Russell Anne Marie L. Carandang, MD Department of Neurosciences East Avenue Medical Center East Avenue, Barangay Central, Diliman, Quezon City Email: rcarandangmd@gmail.com ORCiD: https://orcid.org/0000-0001-8656-4314

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is associated with a 50% increase risk for dementia.¹ In 2014, it was estimated that 3.2 million Filipinos has T2DM. Prevalence rate was 5.9%, occurring among ages 20 to 79 years old, with \$205 as estimated cost per person.² T2DM is also associated with an increased rate of cognitive decline and dementia among elderly people.^{3,4} The median direct medical cost for dementia care in the Philippines was \$238.⁵ The co-occurrence of the two diseases will then translate to a higher medical cost hence identifying predictors of cognitive impairment among patients with T2DM is important.

People with DM showed to have lower performance in mental processing, language, and attention or reasoning.⁶ Poor glycemic control, higher glycosylated hemoglobin (HbA1C) levels, and longer diabetes duration were linked to increased incidence of cognitive impairment.⁷ It predisposed people with DM to treatment-related complications, such as acute severe hypo- or hyperglycemic episodes.⁸ Impairment in executive function and memory were also correlated with reduced gray matter density and glucose metabolism in the brain.¹

Determining the relationship between diabetes mellitus and the factors contributing to cognitive impairment may help recognize patients who are at risk of developing cognitive impairment and help promote preventive strategies.⁶

OBJECTIVES

To determine the predictors of cognitive impairment among Filipino patients diagnosed with Type 2 Diabetes Mellitus at a tertiary government hospital from November 2021 to June 2022.

MATERIALS AND METHODS

Study Design

This study is a cross-sectional analytical study involving patients diagnosed with Type 2 Diabetes Mellitus who were seen at the Diabetes Mellitus Clinic at East Avenue Medical Center Out Patient Department.

The case ascertainment and study approach are described in Figure 1. Type 2 Diabetes patients who consented to join the study were recruited. Patients were screened using the AD8-P questionnaire.

Aging and Dementia 8-P, or more known as AD8-P is a Filipino adaptation of the original AD8.9 The questionnaire includes eight 'yes' or 'no' questions to be answered by the informant or caregiver (Appendix). The questions comprise changes in terms of memory and thinking abilities over the past years. A score of equal or greater than 3 is considered to have cognitive impairment while less than and equal to 2 is normal. This questionnaire was validated by Dominguez et al. last 2021. It showed a high internal consistency and strong correlation with other cognitive assessment tools such as Montreal Cognitive Assessment (MOCA), Mini Mental Status Examination (MMSE), and CDR (Clinical Dementia Rating); as well as with the Lawton Instrumental Activities of Daily Living (IADL). Due to the fact that AD8-P focuses at the intraindividual decline rather than interindividual performance in comparison to a normative value, it has proven to be more sensitive than MOCA-P and MMSE-P. Additionally, it was discovered that the informant's age and educational background have no bearing on AD8-P score.

Measurements

The following data of included subjects were retrieved and recorded – demographic profile including age, sex, body mass index (BMI). Vascular risk factors include history of smoking (current smoker, previous smoker, or never smoked); history of hypertension and its duration; stroke, psychiatric diseases; patients' latest laboratory tests for the past six months including the HbA1C (glycosylated hemoglobin), FBS (fasting blood sugar), total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and estimated glomerular filtration rate (computed based on the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).

Statistical Analysis

Summary statistics were reported as mean and standard deviation (SD) for continuous data with normal distribution or as the median and interquartile range (IQR) for quantitative variables with skewed distribution and as count and percent for qualitative measures. Prevalence of cognitive impairment of patients diagnosed with Type 2 DM with 95% confidence interval based on AD8-P scores were estimated.

The Shapiro-Wilks test was used to determine if continuous variables deviate from a normal (Gaussian) distribution. Pearson chi-square test or Fisher exact test was used in comparing proportions. Pairwise comparisons were based on Bonferroni-adjusted p-values. The independent t-test or Mann-Whitney U test was used in comparing the mean between two groups (cognitive impairment vs. normal cognitive function). The median test was used in comparing the median between the two groups. Univariate and multivariate logistic regression analyses were performed to assess the association of duration of diabetes, demographic sex and age, and clinical patient characteristics with cognitive impairment based on the AD8-P scores. Crude and adjusted odds ratio and 95% confidence interval were reported. Statistical significance was based on *p*-value \leq .05. STATA version 15 (Stata Corp LLC, College Station, TX, US) will be used in data processing and analysis.

Study Population and Sampling Method

Inclusion and Exclusion criteria

Included patients must fulfill the following criteria: (1) Filipino patients diagnosed with Type 2 Diabetes Mellitus; (2) age range of 26-85 years old; (3) no visual or hearing impairment.




Figure 1. Case Ascertainment and Methodology. EAMC – East Avenue Medical Center. T2DM – Type 2 Diabetes Mellitus; AD8-P – Aging and Dementia 8-P. Exclusion criteria include patients who were (1) Diagnosed to have other types of diabetes (Type 1 Diabetes, Gestational Diabetes, Maturity Onset Diabetes of the Young [MODY]); (2) with speech impairment; (3) diagnosed case of psychiatric diseases; and (4) patients who are reluctant to cooperate.

Patients may withdraw their consent to participate at any point in the study, whether verbal or written.

Sample Size

The minimum number of patients for this study is determined using the formula¹⁰:

N =10k/p

where: N is the minimum sample size, p is the smallest of the proportions of negative or positive cases in the population and k the number of independent variables. Based on a local study by Blanquisco¹¹, the rate of mild cognitive impairment among elderly Filipino diabetics is 45%. In this study, there are seven hypothesized independent variables considering sociodemographic and clinical factors affecting cognitive impairment. Thus, the minimum sample size is 156.

RESULTS

Two hundred ninety-five patients were initially identified with Type 2 Diabetes Mellitus at the Diabetes Mellitus Clinic. Seventy-three had other types of diabetes, three of which did not correspond to the age range, and one patient had impairment of speech. Two hundred adult patients diagnosed with Type II Diabetes Mellitus ages 26 to 85 were identified at the Diabetes Mellitus clinic for screening and chart review. However, 29 patients withdrew their consent in joining the study, while 18 patients lacked latest laboratory results in their medical charts.

A total of 171 adult patients were included and screened for cognitive impairment (Figure 2). The prevalence of cognitive impairment was 33 out of 171 or 19.3% (95% CI: 13.9% to 25.7%). Out of 33 patients with cognitive impairment, almost two-thirds of the population are female, have low-educational attainment, three patients (9.1%) have had a previous stroke. The mean duration of the patient's diabetes was 11.2 years, wherein 19 patients (57.6%) had T2DM for more than 10 years. The average HbA1C was at 8.6%. Moreover, two-thirds of the patients were taking oral anti-hypoglycemic agents, while the rest are insulin-requiring.


Comparison with normal cognitive function showed that patients with cognitive impairment have a mean age of 59.6 years old (vs. 55.5 years old, p < 0.029). Also, a higher proportion of patients with cognitive impairment have longer duration of diabetes (11.2 years vs. 6.8 years, p < .002). Comparisons also showed that those with cognitive impairment had a longer duration of diabetes (≥ 10 vs. <5 years, p < .002). There were insignificant differences between the two groups for demographic sex, years of education, and clinical characteristics including BMI, fasting blood sugar, HbA1C levels, lipid profile, and eGFR (Table 1).

Assessment of effects of demographic and clinical characteristics in the development of cognitive impairment showed that at the age 66 years and older and the duration of diabetes had crude associations with cognitive impairment based on the AD8-P scores. (Table 2)

Adjusting for confounders and multi-collinearity, the duration of diabetes was significantly associated with cognitive impairment (Table 2). Notably, the odds of developing cognitive impairment increases as the duration reach 10 years above. Those with T2DM for at least ten years were 2.5 times more likely to develop cognitive impairment, holding the age constant. (OR = 2.5, 95% CI – 1.0 to 5.8, p < 0.043).

DISCUSSION

This study was the first to use the AD8-P as a tool in assessing cognitive impairment among Filipinos with Type





T2DM - Type 2 Diabetes Mellitus; AD8-P - Aging and Dementia 8-P.

2 Diabetes Mellitus. To date, there is no established best neuropsychological tests to evaluate cognitive impairment in diabetes.¹

The prevalence rate of cognitive impairment among Filipino patients in a tertiary government hospital with T2DM was 19.3%. The prevalence was lower in contrast to the study of Blanquisco et al. which only included Filipino patients more than 60 years old.¹¹ This study noted that 69.6% of the cognitively impaired patients were less than 65 years old (Table 1).

The prevalence rate using AD8-P was comparable with the study done in Pakistan assessing cognitive impairment among patients with T2DM.¹²

Characteristic	All Patients (n=171)	Normal Cognitive Function (n=138)	Cognitive Impairment (n=33)	<i>p</i> -value
Sex				
Male	68 (39.8%)	56 (40.6%)	12 (36.4%)	0.697
Female	103 (60.2%)	82 (59.4%)	21 (63.6%)	
Age in years	56.3 ± 9.7	55.5 ± 9.6	59.6 ± 9.4	0.029 [†]
≤44	17 (9.9%)	16 (11.6%)	1 (3.0%)	0.114
45-55	63 (36.8%)	52 (37.7%)	11 (33.3%)	
56-65	61 (35.7%)	50 (36.2%)	11 (33.3%)	
≥66	30 (17.5%)	20 (14.5%)	10 (30.3%)	
Education in years				
≤12	104 (60.8%)	84 (60.9%)	20 (66.7%)	0.978
>12	67 (39.2%)	54 (39.1%)	13 (33.3%)	
Smoking history				
Non-smoker	121 (70.8%)	99 (71.7%)	22 (66.7%)	0.670
Previous smoker	50 (29.2%)	39 (28.3%)	11 (33.3%)	
BMI kg/m²	25.8 (4.7)	26.2 (9.6)	26.2 (4.0)	0.997
Duration of diabetes in years	5.0 (10.0)	6.8 (6.8)	11.2 (9.3)	0.002 [‡]
0-4	78 (45.6%)	67 (48.6%)	11 (33.3%)	
5-9	34 (19.9%)	31 (22.5%)	3 (9.1%)	0.083
≥10	59 (34.5%)	40 (29.0%)	19 (57.6%)	0.002 [‡]
HbA1C %	8.4 (3.9)	8.8 (2.8)	8.6 (2.4)	0.812
Fasting blood sugar in mg/dl	137.4 (92.3)	161.1 (73.8)	156.9 (72.1)	0.769
Total cholesterol in mg/dl	170.2 ± 50.0	171.2 ± 49.8	166.0 ± 51.4	0.588
LDL in mg/dl	89.9 (59.0)	94.2 (41.8)	92.7 (36.1)	0.846
HDL in mg/dl	42.5 ± 11.3	42.5 ± 11.3	42.4 ± 11.7	0.954
Triglycerides in mg/dl	130.2 (94.1)	148.4 (86.1)	160.7 (87.1)	0.463
eGFR in mg/dl	79.0 (44.0)	79.6 (36.1)	71.5 (32.3)	0.241
Hypertension				
Absent	70 (40.9%)	59 (42.8%)	11 (33.3%)	0.335
Present	101 (59.1%)	79 (57.2%)	22 (66.7%)	
Duration of HTN in years	2.0 (8.0)	8.0 (5.9)	9.7 (8.1)	0.285
<1	2 (2.0%)	1 (1.3%)	1 (4.5%)	0.356
1-5	40 (39.6%)	34 (43.0%)	6 (27.3%)	
6-10	33 (32.7%)	25 (31.6%)	8 (36.4%)	
≥11	26 (25.7%)	19 (24.1%)	7 (31.8%)	
Previous stroke				
No	168 (98.2%)	138 (100.0%)	30 (90.9%)	0.007
Yes	3 (1.8%)	0 (0.0%)	3 (9.1%)	
Treatment plan				
Non-insulin requiring	78 (45.6%)	71 (51.4%)	22 (66.7%)	0.125
Insulin-requiring	93 (54.4%)	67 (48.6%)	11 (33.3%)	

AD8-P: Aging and Dementia, HbA1c: glycated hemoglobin, LDL: low-density lipoprotein, HDL: high-density lipoprotein, eGFR: glomerular filtration rate. Data are mean \pm SD, median (IQR) or n (%) on 171 adult patients with Type 2 diabetes, 33 with cognitive impairment based on AD8-P scores \geq 3.

 $^{\dagger}P$ <.05, $^{\ddagger}P$ <.01 vs. normal cognitive function.

The duration of the diabetes mellitus was correlated with the development of cognitive impairment. Similar with international studies, our results were consistent with their findings that the duration of diabetes was a predictor of cognitive dysfunction. Blood glucose abnormalities and insulin resistance were reported to be linked to cognitive impairment in patients with T2DM.^{7,8,10} In comparison to a study done by Blanquisco et al.¹¹, low educational attainment was not a predictor of cognitive impairment. Smoking and lipid profile were comparable to both patients with normal cognition and cognitive impairment. This study was not able to assess the recent episodes of hypoglycemia.

 Table 2. Results of Simple and Multiple Univariate Logistic Regression on Factors Associated with Cognitive Impairment based on AD8-P

Factors	Dependent variable: cognitive impairment					
Factors	Crude OR (95% CI)	p-value	Adjusted ^a OR (95% CI)	p-value		
Sex						
Female	Reference					
Male	0.8 (0.4, 1.8)	0.657				
Age in years						
≤44	Reference					
45-55	3.4 (0.4, 28.3)	0.260	2.8 (0.3, 24.2)	0.343		
56-65	3.5 (0.4, 29.4)	0.245	2.8 (0.3, 23.6)	0.364		
≥66	8.0 (0.9, 69.2)	0.059	6.1 (0.7, 55.6)	0.107		
Education in years						
≤12	Reference					
>12	1.0 (0.5, 2.2)	0.978				
Smoking history						
Non-smoker	Reference					
Previous smoker	1.3 (0.6, 2.9)	0.566				
BMI kg/m²	1.0 (0.9, 1.1)	0.997				
Duration of diabetes in years						
0-4	Reference					
5-9	0.6 (0.2, 2.3)	0.441	0.5 (0.1, 2.0)	0.336		
≥10	2.9 (1.3, 6.7)	0.013†	2.5 (1.0, 5.8)	0.043		
HbA1C %	1.0 (0.9, 1.1)	0.811				
Fasting blood sugar in mg/dl	1.0 (1.0, 1.0)	0.769				
Total cholesterol in mg/dl	1.0 (1.0, 1.0)	0.586				
LDL in mg/dl	1.0 (1.0, 1.0)	0.845				
HDL in mg/dl	1.0 (1.0, 1.0)	0.952				
Triglycerides in mg/dl	1.0 (1.0, 1.0)	0.461				
eGFR in mg/dl	1.0 (1.0, 1.0)	0.239				
Hypertension						
Absent	Reference					
Present	1.5 (0.7, 3.3)	0.325				
Duration of HTN in years						
<1	Reference					
1-5	0.2 (0.0, 3.2)	0.242				
6-10	0.3 (0.0, 5.7)	0.439				
≥11	0.4 (0.0, 6.7)	0.500				
Previous stroke						
No	Reference					
Yes	7x10 [°] (too wide)	0.999				
Treatment plan						
Non-insulin requiring	Reference					
Insulin-requiring	0.5 (0.2, 1.2)	0.118				

HbA1c: glycosylated hemoglobin, LDL: low-density lipoprotein, HDL: high-density lipoprotein, eGFR: glomerular filtration rate.

 $^{\dagger}P$ <.05, $^{\ddagger}P$ <.01 vs. reference, a reduced logistic regression model based on age and duration of diabetes.

Other factors that may also contribute to developing cognitive impairment in patients with T2DM, include increasing age, hypertension, and obesity. These may be due to vascular endothelial dysfunction, inflammation and injury to the blood-brain barrier, development of white matter disease, and demyelination and axonal loss.^{8,11}

A large cohort study by Dove et al., also showed that poorly controlled diabetes was associated with increased risk of cognitive impairment and dementia and may cause adverse outcomes when combined with heart disease and systemic inflammation. They also found out that poorly controlled HbA1c, degree of hyperglycemia rather that the diabetes itself, negatively impacts cognitive health.¹³ These findings were not seen in our study probably due to a smaller sample size.

CONCLUSION

In conclusion, our results showed that 19.3% of Filipino patients with Type 2 Diabetes Mellitus are cognitively impaired and this can occur even in less than 65 years old. The ten years or longer duration of T2DM increases the risk of developing cognitive impairment by 2.5%.

Recommendations

Larger studies may be done to further evaluate the mechanisms and investigate other factors that may be associated with T2DM and cognitive impairment among Filipinos. Cranial imaging will be helpful in ruling out other structural causes of cognitive impairment.

Compliance with Ethical Standards

This study was in accordance with the ethical standards of the Technical Review Board and the Institutional and Ethics Review Board (IERB) of East Avenue Medical Center and with Helsinki Declaration of 1964 and later version. Informed consent was obtained from all patients who were included in the study.

Statement of Authorship

All authors certified fulfillment of ICMJE authorship criteria.

Author Disclosure

All authors declared no conflicts of interest.

Funding Source

The study was funded by the authors.

REFERENCES

- Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr Diab Rep. 2016 Sep;16(9):87. doi: 10.1007/ s11892-016-0775-x. PMID: 27491830; PMCID: PMC5528145.
- Tan GH. Diabetes care in the Philippines. Ann Glob Health. 2015 Nov-Dec;81(6):863-9. doi: 10.1016/j.aogh.2015.10.004. PMID: 27108153.
- Usarel C, Dokuzlar O, Aydin AE, Soysal P, Isik AT. The AD8 (Dementia Screening Interview) is a valid and reliable screening scale not only for dementia but also for mild cognitive impairment in the Turkish geriatric outpatients. Int Psychogeriatr. 2019 Feb;31(2): 223-9. doi: 10.1017/S1041610218000674. PMID: 29923472.
- Li X, Jia S, Zhou Z, Jin Y, Zhang X, Hou C, et al. The role of the Montreal Cognitive Assessment (MoCA) and its memory tasks for detecting mild cognitive impairment. Neurol Sci. 2018 Jun;39(6): 1029-34. doi: 10.1007/s10072-018-3319-0.
- Dominguez J, Jiloca L, Fowler KC, De Guzman MF, Dominguez-Awao JK, Natividad B, et al. Dementia incidence, burden and cost of care: a Filipino community-based study. Front Public Health. 2021 May 14;9:628700. doi: 10.3389/fpubh.2021.628700. PMID: 34055712; PMCID: PMC8160123.
- Espeland MA, Carmichael O, Yasar S, Hugenschmidt C, Hazzard W, Hayden KM, et al. Sex-related differences in the prevalence of cognitive impairment among overweight and obese adults with type 2 diabetes. Alzheimers Dement. 2018 Sep;14(9):1184-92. doi: 10.1016/j.jalz.2018.05.015. PMID: 30201101; PMCID: PMC6338071.
- Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018 Oct;14(10):591-604. doi: 10.1038/s41574-018-0048-7. PMID: 30022099; PMCID: PMC6397437.
- Biessels GJ, Whitmer RA. Cognitive dysfunction in diabetes: how to implement emerging guidelines. Diabetologia. 2020 Jan;63(1): 3-9. doi: 10.1007/s00125-019-04977-9. PMID: 31420699; PMCID: PMC6890615.
- Dominguez JC, de Guzman MFP, Joson MLC, Fowler K, Natividad BP, Cruz PS, et al. Validation of AD8-Philippines (AD8-P): a brief informant-based questionnaire for dementia screening in the Philippines. Int J Alzheimers Dis. 2021 Oct;2021: 7750235. doi:10.1155/2021/7750235. PMID: 34754516; PMCID: PMC8572610.
- Xia SS, Xia WL, Huang JJ, Zou HJ, Tao J, Yang Y. The factors contributing to cognitive dysfunction in type 2 diabetic patients. Ann Transl Med. 2020 Feb;8(4):104. doi: 10.21037/atm.2019.12.113. PMID: 32175397; PMCID: PMC7049020
- Blanquisco L, Abejero JE, Buno Ii B, Trajano-Acampado L, Cenina A, Santiago D. Factors associated with mild cognitive impairment among elderly Filipinos with type 2 diabetes mellitus. J ASEAN Fed Endocr Soc. 2017;32(2):145-50. doi: 10.15605/jafes.032.02.08. PMID: 33442098; PMCID: PMC7784175.
- Mahmood SBZ, Zafar A, Almas A. Cognitive impairment in type 2 diabetes mellitus: an observational study from lower middleincome country. Indian J Endocrinol Metab. 2022 Mar-Apr;26(2): 189-90. doi: 10.4103/ijem.ijem_18_22. PMID: 35873938; PMCID: PMC9302410.
- 13. Dove A, Shang Y, Xu, W, Grande G, Laukka EJ, Fratiglioni L, et al. The impact of diabetes on cognitive impairment and its progression to dementia. Alzheimers Dement. 2021 Nov;17(11):1769-78. doi:10.1002/alz.12482. PMID: 34636485.

APPENDIX

AD8-P Dementia Screening Interview

AD8-P (Filipino Version)

AD8 Dementia Screening Interview by the Dementia Society of the Philippines

	Tandaan, ang "OO, may pagbabago" ay tinutukoy na mayroong pagbabago sa mga nagdaang taon sanhi ng problema sa pag-iisip at sa memorya	OO, May pagbabago	WALA, Walang pagbabago	N/A Hindi alam
1	Problema sa paghusga (halimbawa, problema sa pag-gawa ng desisyon, maling desisyon pampinansiyal)		in in	^C
2	Nabawasan ang interes sa libangan at aktibidades	- il	R	
3	Naguulit-ulit ng mga tanong, kuwento o pahayag	2		
	Nahihirapan matutong gumamit ng mga kasangkapan, gamit pambahay o ibang mga gamit (halimbawa, "cellphone", "remote control", TV, VCD o karaoke)			-
5	Pagkalimot sa tamang buwan o taon			
6	Nahihirapan mangasiwa ng komplikadong transaksyong pampinansyal (halimbawa, pagbabadyet ng gastusin, pagbayad ng buwis at ibang mga bayarin tulad ng kuryente at tubig)			
7	Nahihirapan sa pagalala ng mga "appointments" o tipanan			
8	Araw-araw na may problema sa pag-iisip o memorya			
KAB	JUANG PUNTOS			

Copyright ©2005 by Washington University in St. Louis, MO. All Rights Reserved.